Liječnički vjesnik, Vol. 138 No. 1-2, 2016.
Professional paper
CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES
Dario Rahelić
Velimir Altabas
Miro Bakula
Stjepan Balić
Ines Balint
Biserka Bergman Marković
Nenad Bičanić
Igor Bjelinski
Velimir Božikov
Silvija Canecki Varžić
Nikica Car
Maja Cigrovski Berković
Željka Crnčević Orlić
Marin Deškin
Ema Drvodelić Šunić
Nives Gojo Tomić
Vesna Goldoni
Marina Gradišer
Davorka Herman Mahečić
Marica Jandrić Balen
Dubravka Jurišić Eržen
Sanja Klobučar Majanović
Slaven Kokić
Mladen Krnić
Ivan Kruljac
Ana-Marija Liberati-Čižmek
Martina Lukšić
Srećko Marušić
Tomas Matić
Željko Metelko
Gorana Mirošević
Sanja Mlinarić Vrbica
Ivana Pavlić Renar
Dragomir Petric
Manja Prašek
Ivana Prpić-Križevac
Maja Radman
Dragan Soldo
Tereza Šarić
Sandi Tešanović
Tina Tičinović Kurir
Tamara Turk Wensveen
Marija Vrca Botica
Milan Vrkljan
Vanja Zjačić Rotkvić
Čedomir Zorić
Željko Krznarić
Abstract
Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the pharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetes’ patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglycemia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes.
Keywords
Diabetes mellitus, type 2 – drug therapy, physiopathology, complications; Hypoglycemic agents – therapeutic use; Insulin – therapeutic use; Practice guidelines as topic; Croatia
Hrčak ID:
172812
URI
Publication date:
29.2.2016.
Visits: 8.027 *